(S)-18-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-19,19-dimethyl-16-oxo-4,7,10,13-tetraoxa-17-azaicosan-1-oic acid
95%
- Product Code: 233419
CAS:
2172820-12-9
| Molecular Weight: | 706.85 g./mol | Molecular Formula: | C₃₄H₅₀N₄O₁₀S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD32693336 | |
| Melting Point: | Boiling Point: | 950.9±65.0 °C(Predicted) | |
| Density: | 1.254±0.06 g/cm3(Predicted) | Storage Condition: | -20°C, away from light, dry |
Product Description:
Used in pharmaceutical research as a key intermediate in the synthesis of GLP-1 receptor agonists, particularly in the development of long-acting antidiabetic drugs. Its structure enables conjugation with proteins or peptides to enhance stability and prolong half-life in vivo. Commonly employed in the preparation of semaglutide analogs due to its ability to facilitate albumin binding through fatty acid side chain mimicry, improving pharmacokinetic properties. Also utilized in prodrug strategies where controlled release of the active moiety is required. Its polyethylene glycol (PEG) spacer units enhance solubility and reduce aggregation, making it suitable for subcutaneous formulations.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 0.050 | 10-20 days | $654.65 |
+
-
|
| 0.100 | 10-20 days | $1,033.25 |
+
-
|
(S)-18-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-19,19-dimethyl-16-oxo-4,7,10,13-tetraoxa-17-azaicosan-1-oic acid
Used in pharmaceutical research as a key intermediate in the synthesis of GLP-1 receptor agonists, particularly in the development of long-acting antidiabetic drugs. Its structure enables conjugation with proteins or peptides to enhance stability and prolong half-life in vivo. Commonly employed in the preparation of semaglutide analogs due to its ability to facilitate albumin binding through fatty acid side chain mimicry, improving pharmacokinetic properties. Also utilized in prodrug strategies where controlled release of the active moiety is required. Its polyethylene glycol (PEG) spacer units enhance solubility and reduce aggregation, making it suitable for subcutaneous formulations.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :